What hip patients typically pay

A ChondroFiller hip injection in the UK broadly costs £6,500–£9,500 on an all-inclusive, self-funded basis — the figure most patients planning ahead should work with.

That range reflects the three-tier price architecture that underpins all UK ChondroFiller tariffs: one box at £3,000, two boxes at £5,500, or three boxes at £8,000. The hip joint covers a larger surface area than a focal knee defect, so hip cases typically fall into the two- or three-box tier rather than the single-box starting point most often quoted for the knee.

The exact tier — and therefore the confirmed cost — is established only once a pre-procedure MRI has been reviewed by the treating clinician. Any figure given before imaging is assessed should be treated as a guide estimate rather than a fixed commitment.

London Cartilage Clinic on Harley Street is currently the only UK provider with publicly stated fixed tariffs for ChondroFiller; their pricing is the benchmark all published sources reference. Patients who proceed through another UK centre should request written confirmation that the quoted figure covers equivalent scope before committing.

What the all-inclusive price covers

The most important difference when comparing this cost with surgical cartilage repair is how the billing is structured. Hip arthroscopy or open cartilage procedures typically generate several separate invoices — surgeon, anaesthetist, hospital or theatre facility, and post-operative imaging — each charged independently. The ChondroFiller figure is a single all-in tariff with no additional line items.

That tariff covers every clinical touchpoint: initial consultation, pre-procedure MRI review, real-time ultrasound guidance on the day, the collagen scaffold implant, intravenous antibiotic cover, and a six-week follow-up appointment.

The implant itself is the dominant cost within that package. As a CE-marked Class III medical device manufactured by Meidrix Biomedicals GmbH in Germany and imported under individual patient prescription, it carries a very different supply-chain cost from a standard injectate held in clinic stock.

The procedure is an outpatient ultrasound-guided injection under local anaesthesia, lasting roughly 30–45 minutes with same-day discharge. There is no theatre fee, no anaesthetist charge, and no hospital admission — costs that would appear on a surgical bill and can significantly inflate the apparent gap between the two pathways when compared on headline figures alone.

Why it costs more than other hip injections

The regulatory classification behind that supply-chain cost is worth understanding, because it also explains why ChondroFiller sits in a different clinical category from the injections most hip patients encounter first.

Corticosteroid and hyaluronic acid injections — both widely used for hip pain — are palliative or symptom-management therapies. Corticosteroid reduces intra-articular inflammation; hyaluronic acid supplements joint fluid to ease friction and movement. Both serve legitimate roles at the right stage of hip arthritis, and both are typically inexpensive stock-held products dispensed from a clinic pharmacy.

ChondroFiller carries a CE-marked Class III designation — the highest risk tier in European medical device regulation — because its mechanism is fundamentally active rather than palliative. Once inside the hip joint, the murine-derived Type I collagen scaffold undergoes in-situ gelation to form a three-dimensional hydrogel matrix. This process — acellular matrix-induced chondrogenesis — means the scaffold recruits the patient's own progenitor cells from surrounding tissue to support the body's own cartilage repair processes. That active biological participation is what triggers Class III classification, and Class III devices face substantially more demanding manufacturing controls, clinical evidence requirements, and importation regulations than standard injectables.

Each unit is also ordered under individual patient prescription and imported from Meidrix Biomedicals GmbH in Germany for that specific patient, rather than stocked in advance like a viscosupplement. Different clinical intent, different regulatory burden, different supply chain: those three factors together account for the price differential — not billing margin alone.

Why ChondroFiller is not available on the NHS

No GP referral unlocks this treatment, and no NHS waiting list exists to join. The gap between ChondroFiller and NHS provision is structural — a matter of commissioning policy, not capacity or waiting time.

The clearest expression of that gap is NICE guidance. NICE HealthTech Guidance HTG728, which addresses single-step scaffold insertion for cartilage defects, applies to the knee only. No equivalent NICE commissioning guidance has been issued for the hip joint, which means there is no approved pathway through which a GP or NHS orthopaedic consultant could refer a patient for publicly funded ChondroFiller treatment, regardless of how appropriate the clinical picture appears.

Beyond the absence of specific guidance, NHS commissioning of Class III regenerative devices ordinarily requires robust randomised controlled trial evidence demonstrating superiority over already-funded alternatives. The published data on ChondroFiller outcomes — including modified Harris Hip Score improvement data for the hip and reported success rates in the region of 70–85% for symptom relief — is encouraging, but the evidence base is drawn predominantly from non-UK studies and has not yet been considered sufficient to clear that commissioning threshold for hip indications.

The NHS does fund cartilage repair for appropriate patients through Autologous Chondrocyte Implantation at a small number of specialist centres, including the Royal National Orthopaedic Hospital in Stanmore and the Robert Jones and Agnes Hunt Orthopaedic Hospital in Shropshire. ACI is, however, a staged surgical procedure involving laboratory cell culture; ChondroFiller occupies a different niche as a single-session injectable scaffold. The two are not in competition for the same commissioning slot.

Major UK private medical insurers — including Bupa and AXA — do not currently cover ChondroFiller either, meaning patients must self-fund the entire cost without PMI reimbursement.

Which hip patients are suitable candidates

Suitability for ChondroFiller depends primarily on the nature of the cartilage damage rather than on age or activity level alone.

The treatment is best matched to patients with an isolated, focal cartilage defect in the hip joint — Grade III or IV on standard cartilage grading scales, meaning the damage is deep but confined to a specific area rather than spread across the joint surface. Equally important is the underlying osteoarthritis stage: Tönnis grade below 2 is the accepted threshold. Tönnis grading is a plain-radiograph measure of hip arthritis severity; a grade of 0 or 1 indicates minimal or early joint-space changes, while grade 2 and above suggests moderate-to-advanced degeneration across the joint as a whole. Patients in the lower Tönnis bands still have a structurally sound enough hip environment for the scaffold to bed in and support the body's own repair processes.

Diffuse, advanced hip osteoarthritis — where widespread cartilage loss affects most of the joint surface — falls outside this indication. In those cases, hip replacement or another salvage pathway is generally more appropriate, and a clinician would advise accordingly at consultation.

Suitability is not self-confirmed: the final determination follows MRI review by the treating clinician, which is also the step that establishes defect size and the number of product boxes required. Patients should not assume eligibility before imaging has been assessed.

One practical planning consideration: hip cases require approximately six weeks of protected weight-bearing after the injection while the collagen scaffold stabilises and progenitor cells migrate into the matrix. This is not a deterrent in most cases, but it is relevant for anyone with work or caring commitments that make partial weight-bearing impractical in the short term.

Candidates who are generally not suitable include those with Tönnis grade 2 or above osteoarthritis, active systemic inflammatory arthritis (such as rheumatoid arthritis), or joint infection. These are the disqualifying factors a clinician will check for at first assessment, even when a patient's self-description sounds otherwise appropriate.

How to access ChondroFiller for a hip condition

Accessing ChondroFiller for a hip problem in the UK requires self-referral to a private specialist centre; no GP letter is a prerequisite.

The practical first step is finding a clinic with specific experience placing ChondroFiller in the hip joint — hip cases differ from knee cases in product volume and anatomy, and it is reasonable to ask about that experience before booking. Before committing, request written confirmation that the quoted figure is genuinely all-inclusive and matches the scope of the standard tariff. The exact cost cannot be finalised until a clinician has reviewed hip MRI imaging of the affected joint; any figure given before that point is an estimate. Patients who already hold recent hip MRI scans should bring them to the consultation, which can avoid a repeat scan and move the assessment forward.

When comparing non-London providers, three questions are worth raising with any clinic: whether their team has placed ChondroFiller in the hip rather than the knee alone; what the written cost confirmation will specify; and what the follow-up support looks like across the six-week recovery.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment, with clinics in Sleaford and Grantham serving patients across Lincolnshire and the wider non-London catchment.